Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10227647 | Biomaterials | 2014 | 11 Pages |
Abstract
A lipid-cisplatin conjugate was synthesized for super-molecular assembly with lipids to form a new generation of liposomal cisplatin formulation, lipocisplatin. In vitro, lipocisplatin has higher efficacy in human ovarian cancer A2780 and human breast cancer MCF-7 with the murine breast cancer cell line 4T1 which is currently an established model for stage IV breast cancer as the most sensitive strain. Moreover, lipocisplatin demonstrated a greater MTD value and relatively longer blood circulation as compared to cisplatin. Lipocisplatin preferentially accumulate drugs to the tumor site, resulting in a better tumor inhibition efficacy. Moreover, lipocisplatin exceeds the size cutoff for kidney clearance, hence it bypasses the nephrotoxicity of cisplatin which is a major curse of one of the most efficient anticancer drugs nowadays in clinic. The results here indicated lipocisplatin may be translated into a new generation of liposomal based cisplatin drug in clinic.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Qun Li, Yuantong Tian, Dandi Li, Jianfeng Sun, Donglei Shi, Lin Fang, Yong Gao, Haiyan Liu,